Metastatic renal cell carcinoma (mRCC) is associated with a high risk of thromboembolism (TE).
We investigated whether immunotherapy (IO) increases the hypercoagulable state in this high-risk population.
Metastatic renal cell carcinoma (mRCC) is associated with a high risk of thromboembolism (TE).
We investigated whether immunotherapy (IO) increases the hypercoagulable state in this high-risk population.